Bavarian Nordic A/S: Business Overview, Financials & Competitive Analysis
Bavarian Nordic A/S scores 8/10 on the AskCyborg Cyborg Score (Strong). Essential vaccine supplier with dual-revenue-stream growth strategy, government contracts providing stability while travel health business accelerates toward double-digit expansion. Revenue for Q1 2025 increased 62% to DKK 1,347 million with strong performance in both Travel Health and Public Preparedness. The company has diversified revenue, government demand stability, and accelerating.
What is Bavarian Nordic A/S's industry? Bavarian Nordic A/S (bavarian-nordic.com) operates in Biotechnology / Vaccines / Pharmaceuticals. AskCyborg classifies Bavarian Nordic A/S under Biotechnology / Vaccines / Pharmaceuticals in its company registry.
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company supplies mpox and smallpox vaccines to governments and international organizations, and has a portfolio of travel vaccines. Th...
Cyborg Score thesis
Essential vaccine supplier with dual-revenue-stream growth strategy, government contracts providing stability while travel health...
Read the full analyst-debate transcript →Get the Latest Bavarian Nordic A/S Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeBavarian Nordic A/S Overview
Pro stress-test →Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company supplies mpox and smallpox vaccines to governments and international organizations, and has a portfolio of travel vaccines. The firm is positioned as a critical supplier of public health preparedness solutions and expanding travel health products.
Strategic Profile
Pro stress-test →Bavarian Nordic is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. Travel Health business demonstrates 52% growth year-over-year, ahead of strategic goal of average annual growth rate of 10-12% until 2027. The company leverages dual revenue streams from government contracts and commercial travel vaccine sales with strong recent momentum.
Competitive Landscape
Pro stress-test →Bavarian Nordic competes in the global vaccine market against diversified players like Novartis and larger pharmaceutical companies with broader portfolios. The company's competitive advantages include focus on endemic diseases and underserved travel vaccines, established manufacturing scale, and preferred supplier relationships with governments for biodefense applications. Barriers to entry are high due to regulatory complexity and manufacturing expertise requirements.
Industry Context
Bavarian Nordic A/S operates in Biotechnology / Vaccines / Pharmaceuticals.
Key facts
Founded: 1992 · Headquarters: Hellerup, Denmark · Employees: 1,605 · Revenue: $1.02B · Market cap: $2.44B